ADC Therapeutics reports Q3 2026 results with $21M revenue and cash runway into 2029
FROM THE WIRE · PRNEWSWIRE.COM
Third quarter 2026 net product revenue of $21 million; cash and cash equivalents of $189.2 million as of September 30, 2026 Strategic financial restructuring strengthens balance sheet, extending expected cash runway into 2029 Abstracts accepted for presentation at ASH 2026…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: neutralQuarterly results of a biotech whose financial restructuring strengthens its liquidity.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Q3 net product revenue was $21 million.
- 02Cash and equivalents were $189.2 million as of September 30, 2026.
- 03The cash runway is extended into 2029 following the restructuring.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets